Key takeaways
- An economic evaluation in JAMA Network Open found that MFN pricing for Medicare GLP-1s would generate $56.3 billion in downstream healthcare savings over 10 years.
- Despite these massive clinical savings, the study projects a net Medicare spending increase of $17.6 billion over a decade.
- Platforms like TrumpRx.gov offer MFN-priced Wegovy and Zepbound, but clinical experts note that a $245 monthly cost remains a barrier for many seniors.
A new economic evaluation published in JAMA Network Open has revealed that implementing Most Favored Nation (MFN) pricing for GLP-1 receptor agonists under Medicare could yield massive downstream clinical dividends, even as overall drug spending rises.
According to the study, expanding Medicare coverage for obesity treatment using MFN-level drug pricing would generate $56.3 billion in healthcare savings over a 10-year period due to improved clinical outcomes. This projection offers critical context on the financial sustainability of discounted GLP-1 platforms like the federal government's TrumpRx.gov, while highlighting the complex balance between upfront drug costs and long-term medical savings.
For US consumers navigating the crowded landscape of medical weight loss, the study underscores a shifting tide in GLP-1 affordability—though policy experts and clinicians warn that out-of-pocket barriers remain.
The Math Behind the 10-Year Medicare Budget Impact
Led by Dariush Mozaffarian, MD, DrPH, of the Food is Medicine Institute and the Friedman School of Nutrition Science and Policy at Tufts University, the researchers modeled the financial trajectory of GLP-1 coverage. The economic evaluation analyzed data from 15.6 million current Medicare beneficiaries and 14.4 million individuals projected to become eligible over the next decade.
In the study's base-case scenario, researchers assumed:
- An average monthly drug price of $245
- A 30% patient uptake rate
- A 40% treatment adherence rate
Under these parameters, projected Medicare spending on GLP-1 medications for obesity treatment totaled $73.9 billion over 10 years. This total comprises $23.4 billion spent during the initial treatment phases and $50.5 billion for ongoing maintenance therapy.
Crucially, the study estimated that the clinical benefits of these medications would yield $56.3 billion in direct healthcare cost savings. When offsetting the $73.9 billion drug spend with these clinical savings, the net increase in Medicare spending was calculated at $17.6 billion over the decade.
While the policy would result in a net cost increase to the Medicare program, the substantial $56.3 billion reduction in downstream medical expenses highlights how effectively GLP-1 therapies can mitigate the expensive complications of obesity, such as cardiovascular disease and type 2 diabetes.
MFN Pricing and the Role of TrumpRx.gov
The economic analysis comes at a time of unprecedented disruption in the US weight-loss market. On February 5, 2026, the US government launched its TrumpRx.gov platform, offering MFN-priced prescriptions directly to eligible Americans.
As of August 10, 2026, the platform features major brand-name GLP-1 medications approved for weight management, including tirzepatide (Zepbound, Eli Lilly) and semaglutide (Wegovy, Novo Nordisk). The MFN pricing model has dramatically lowered out-of-pocket costs on the site relative to standard retail pricing. For example:
- Semaglutide 1.5-mg tablets (30-count): Available on TrumpRx.gov for $149, compared to a standard wholesale acquisition cost of $1,349.02.
- Tirzepatide 2.5-mg vials: Priced at $299 on the platform, compared to a standard wholesale acquisition cost of $1,087.00.
While the TrumpRx.gov platform expanded on May 18, 2026, to include generic medications for other chronic diseases, generic or compounded versions of GLP-1s for obesity have not yet been added to the government site.
The Clinical Reality: Even "Discounted" Costs Pose Barriers
While MFN pricing represents a massive drop from standard US retail prices, clinicians on the ground caution that a $245 monthly price tag is still out of reach for many.
In an interview with Physician's Weekly discussing the JAMA Network Open study, Elizabeth Kazarian, MD, a double-board-certified family and obesity medicine physician at PMA Health, noted that older adults have historically been left out of the GLP-1 revolution due to a lack of Medicare coverage.
"Bringing the price down to around $250 instead of the usual retail cost of more than $1,000 will lower the barrier to entry for many patients," Dr. Kazarian told Physician's Weekly. However, she emphasized that many Medicare beneficiaries manage multiple chronic conditions and take several prescriptions concurrently. "Many Medicare beneficiaries will still struggle to pay around $250 each month for one of their medications."
Furthermore, Dr. Kazarian pointed out that because participation in these pricing frameworks may vary, not all Medicare Part D plans will automatically opt in to cover these medications, leaving some patients with few options but to pay entirely out of pocket.
What This Means if You Are Shopping for GLP-1s Online
If you are currently looking for affordable weight-loss medications in the US, this policy debate highlights why finding the right channel is so critical.
If you do not qualify for MFN pricing through Medicare or federal programs, or if your specific insurance plan does not cover brand-name drugs like Wegovy or Zepbound, you still have highly accessible options:
- Compare Commercial Telehealth Providers: Online health platforms offer a streamlined path to weight-loss treatments. To find the most affordable programs and compare membership fees, consult our guide to the cheapest telehealth GLP-1 services.
- Understand Compounded vs. Brand-Name Options: Because brand-name drugs remain costly and suffer from supply constraints, many patients turn to compounding pharmacies. Learn about the regulatory differences, safety profiles, and cost structures in our guide to compounded vs. brand-name semaglutide.
- Verify Insurance Rules: Navigating coverage can be incredibly complex. To see if your commercial insurance or employer plan might pay for your treatment, review our breakdown of what insurance covers GLP-1 medications.
If you are ready to explore your medical weight-loss options, you can use our interactive questionnaire to find a provider, or visit our providers directory to compare plans, pricing, and treatment options side-by-side.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare professional before starting or changing any medical treatment or weight-loss medication.